Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vbi Vaccines Inc CS (NQ: VBIV )

1.085 -0.145 (-11.79%)
Streaming Delayed Price Updated: 3:35 PM EDT, Aug 18, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vbi Vaccines Inc CS

< Previous 1 2 Next >
VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Results of Annual General Meeting
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Participate in the Jefferies Healthcare Conference
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Presents Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at the 2022 ASCO Annual Meeting
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces UK MHRA Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B Vaccine
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Abstract Accepted for Oral Presentation at EASL 2022
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Presented Health Economics and Outcomes Research for PreHevbrio™ at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2022
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Reports First Quarter 2022 Financial Results and Provides Corporate Update
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces European Commission Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B Vaccine
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Data from VBI-1901 in Recurrent Glioblastoma Patients Selected for Poster Discussion at the 2022 ASCO Annual Meeting
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus Program
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces PreHevbrio™ is Now Available in the United States for the Prevention of Hepatitis B in Adults
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Participate in the 32nd Annual Oppenheimer Healthcare Conference
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Receives Positive CHMP Opinion for 3-Antigen Hepatitis B Vaccine for Immunization Against Hepatitis B Infection in Adults in the European Union
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Participate in the B. Riley Securities 2022 Oncology Investor Conference
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Dosing of First Patient in Second Phase 2 Study in Chronic Hepatitis B Patients as Part of Expansion of Clinical Collaboration With Brii Bio
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Filing of New Drug Submission for 3-Antigen Hepatitis B Vaccine to Health Canada
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Present New Overall Survival Data from Phase 2a Study in Recurrent GBM at the World Vaccine & Immunotherapy Congress 2021
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces FDA Approval of PreHevbrio™ for the Prevention of Hepatitis B in Adults
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Participate in Jefferies London Healthcare Conference
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Third Quarter 2021 Financial Results and Provides Corporate Update
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces e-Poster Presentation of 3-Antigen Prophylactic Hepatitis B Vaccine Data at The Liver Meeting® 2021
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, CONSTANT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Journal of the American Medical Association Network Open
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Participate in Upcoming Investor Conferences
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces New Preclinical Data and Initiation of VBI-2905 Clinical Study Targeting Broadened Immunity Against COVID-19 and Variants of Concern
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Second Quarter 2021 Financial Results and Provides Corporate Update
From VBI Vaccines Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.